AXSOME THERAPEUTICS ($AXSM) posted quarterly earnings results for Q1 2026 on Monday, May 4th. The company reported earnings of -$1.26 per share, missing estimates of -$0.91 by $0.35. The company also reported revenue of $191,200,000, missing estimates of $192,976,860 by $-1,776,860.
You can see Quiver Quantitative's $AXSM stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
AXSOME THERAPEUTICS Insider Trading Activity
AXSOME THERAPEUTICS insiders have traded $AXSM stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.
Here’s a breakdown of recent trading of $AXSM stock by insiders over the last 6 months:
- HERRIOT TABUTEAU (Chief Executive Officer) has made 0 purchases and 10 sales selling 415,736 shares for an estimated $63,361,164.
- MARK E SAAD has made 0 purchases and 2 sales selling 37,577 shares for an estimated $6,206,968.
- MARK L. JACOBSON (Chief Operating Officer) sold 35,378 shares for an estimated $5,726,990
- MARK COLEMAN sold 25,000 shares for an estimated $4,027,750
- ARI MAIZEL (Chief Commercial Officer) has made 0 purchases and 2 sales selling 15,000 shares for an estimated $2,751,450.
- NICK PIZZIE (Chief Financial Officer) sold 12,000 shares for an estimated $2,255,040
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
AXSOME THERAPEUTICS Hedge Fund Activity
We have seen 205 institutional investors add shares of AXSOME THERAPEUTICS stock to their portfolio, and 166 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MACQUARIE GROUP LTD removed 1,084,536 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $198,079,655
- FAIRMOUNT FUNDS MANAGEMENT LLC removed 815,176 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $148,883,744
- RTW INVESTMENTS, LP removed 628,902 shares (-41.5%) from their portfolio in Q4 2025, for an estimated $114,862,661
- PRICE T ROWE ASSOCIATES INC /MD/ added 472,422 shares (+45.5%) to their portfolio in Q4 2025, for an estimated $86,283,154
- BVF INC/IL removed 441,000 shares (-90.6%) from their portfolio in Q4 2025, for an estimated $80,544,240
- ROCKEFELLER CAPITAL MANAGEMENT L.P. added 412,404 shares (+7188.5%) to their portfolio in Q4 2025, for an estimated $75,321,466
- ASSENAGON ASSET MANAGEMENT S.A. added 397,976 shares (+85.0%) to their portfolio in Q1 2026, for an estimated $67,265,903
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
AXSOME THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $AXSM in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Leerink Partners issued a "Outperform" rating on 01/28/2026
- HC Wainwright & Co. issued a "Buy" rating on 01/20/2026
- UBS issued a "Buy" rating on 01/06/2026
- Needham issued a "Buy" rating on 12/31/2025
- Mizuho issued a "Outperform" rating on 11/06/2025
To track analyst ratings and price targets for AXSOME THERAPEUTICS, check out Quiver Quantitative's $AXSM forecast page.
AXSOME THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $AXSM recently. We have seen 12 analysts offer price targets for $AXSM in the last 6 months, with a median target of $226.5.
Here are some recent targets:
- Ami Fadia from Needham set a target price of $255.0 on 05/01/2026
- Ashwani Verma from UBS set a target price of $259.0 on 04/10/2026
- Yatin Suneja from Guggenheim set a target price of $245.0 on 03/25/2026
- Rudy Li from Wolfe Research set a target price of $230.0 on 02/24/2026
- Leonid Timashev from RBC Capital set a target price of $222.0 on 02/24/2026
- Benjamin Burnett from Wells Fargo set a target price of $202.0 on 02/24/2026
- Andrew Tsai from Jefferies set a target price of $245.0 on 02/03/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
